A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection.

Trial Profile

A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Foralumab (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NovImmune SA
  • Most Recent Events

    • 24 Mar 2012 Primary endpoint identified as (serum creatinine levels) as reported by ClinicalTrials.gov.
    • 24 Mar 2012 Additional locations (Poland, United Kingdom) added as reported by European Clinical Trials Database record.
    • 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top